The global Gene Engineered Subunit Vaccine market size was valued at US$ million in 2023. With growing demand in downstream market, the Gene Engineered Subunit Vaccine is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Gene Engineered Subunit Vaccine market. Gene Engineered Subunit Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Gene Engineered Subunit Vaccine. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Gene Engineered Subunit Vaccine market.
A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product鈥攑rotein or polypeptide.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Gene Engineered Subunit Vaccine market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Gene Engineered Subunit Vaccine market. It may include historical data, market segmentation by Type (e.g., Therapeutic Gene Engineered Subunit Vaccine, Preventative Gene Engineered Subunit Vaccine), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Gene Engineered Subunit Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Gene Engineered Subunit Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Gene Engineered Subunit Vaccine industry. This include advancements in Gene Engineered Subunit Vaccine technology, Gene Engineered Subunit Vaccine new entrants, Gene Engineered Subunit Vaccine new investment, and other innovations that are shaping the future of Gene Engineered Subunit Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Gene Engineered Subunit Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Gene Engineered Subunit Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Gene Engineered Subunit Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Gene Engineered Subunit Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Gene Engineered Subunit Vaccine market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Gene Engineered Subunit Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Gene Engineered Subunit Vaccine market.
麻豆原创 Segmentation:
Gene Engineered Subunit Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Therapeutic Gene Engineered Subunit Vaccine
Preventative Gene Engineered Subunit Vaccine
Segmentation by application
Human Use
Veterinary Use
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
GSK
Tiantan
Pulike
Greffex
CureVac
Yebio
Sanofi Pasteur SA
Virbac
Pfizer Inc.
Walvax Biotechnology
Kontec
Novavax
Sanofi Pasteur
Bharat Biotech
GlaxoSmithKline
Pfizer
Moderna
Key Questions Addressed in this Report
What is the 10-year outlook for the global Gene Engineered Subunit Vaccine market?
What factors are driving Gene Engineered Subunit Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gene Engineered Subunit Vaccine market opportunities vary by end market size?
How does Gene Engineered Subunit Vaccine break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Gene Engineered Subunit Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Gene Engineered Subunit Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Gene Engineered Subunit Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Gene Engineered Subunit Vaccine Segment by Type
2.2.1 Therapeutic Gene Engineered Subunit Vaccine
2.2.2 Preventative Gene Engineered Subunit Vaccine
2.3 Gene Engineered Subunit Vaccine Sales by Type
2.3.1 Global Gene Engineered Subunit Vaccine Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Gene Engineered Subunit Vaccine Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Gene Engineered Subunit Vaccine Sale Price by Type (2019-2024)
2.4 Gene Engineered Subunit Vaccine Segment by Application
2.4.1 Human Use
2.4.2 Veterinary Use
2.5 Gene Engineered Subunit Vaccine Sales by Application
2.5.1 Global Gene Engineered Subunit Vaccine Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Gene Engineered Subunit Vaccine Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Gene Engineered Subunit Vaccine Sale Price by Application (2019-2024)
3 Global Gene Engineered Subunit Vaccine by Company
3.1 Global Gene Engineered Subunit Vaccine Breakdown Data by Company
3.1.1 Global Gene Engineered Subunit Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Gene Engineered Subunit Vaccine Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Gene Engineered Subunit Vaccine Revenue by Company (2019-2024)
3.2.2 Global Gene Engineered Subunit Vaccine Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Gene Engineered Subunit Vaccine Sale Price by Company
3.4 Key Manufacturers Gene Engineered Subunit Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gene Engineered Subunit Vaccine Product Location Distribution
3.4.2 Players Gene Engineered Subunit Vaccine Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Gene Engineered Subunit Vaccine by Geographic Region
4.1 World Historic Gene Engineered Subunit Vaccine 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Gene Engineered Subunit Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Gene Engineered Subunit Vaccine 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Gene Engineered Subunit Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Gene Engineered Subunit Vaccine Sales Growth
4.4 APAC Gene Engineered Subunit Vaccine Sales Growth
4.5 Europe Gene Engineered Subunit Vaccine Sales Growth
4.6 Middle East & Africa Gene Engineered Subunit Vaccine Sales Growth
5 Americas
5.1 Americas Gene Engineered Subunit Vaccine Sales by Country
5.1.1 Americas Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
5.1.2 Americas Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
5.2 Americas Gene Engineered Subunit Vaccine Sales by Type
5.3 Americas Gene Engineered Subunit Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Engineered Subunit Vaccine Sales by Region
6.1.1 APAC Gene Engineered Subunit Vaccine Sales by Region (2019-2024)
6.1.2 APAC Gene Engineered Subunit Vaccine Revenue by Region (2019-2024)
6.2 APAC Gene Engineered Subunit Vaccine Sales by Type
6.3 APAC Gene Engineered Subunit Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Gene Engineered Subunit Vaccine by Country
7.1.1 Europe Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
7.1.2 Europe Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
7.2 Europe Gene Engineered Subunit Vaccine Sales by Type
7.3 Europe Gene Engineered Subunit Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Gene Engineered Subunit Vaccine by Country
8.1.1 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Type
8.3 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gene Engineered Subunit Vaccine
10.3 Manufacturing Process Analysis of Gene Engineered Subunit Vaccine
10.4 Industry Chain Structure of Gene Engineered Subunit Vaccine
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gene Engineered Subunit Vaccine Distributors
11.3 Gene Engineered Subunit Vaccine Customer
12 World Forecast Review for Gene Engineered Subunit Vaccine by Geographic Region
12.1 Global Gene Engineered Subunit Vaccine 麻豆原创 Size Forecast by Region
12.1.1 Global Gene Engineered Subunit Vaccine Forecast by Region (2025-2030)
12.1.2 Global Gene Engineered Subunit Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Gene Engineered Subunit Vaccine Forecast by Type
12.7 Global Gene Engineered Subunit Vaccine Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.1.3 Merck Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.2.3 GSK Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Tiantan
13.3.1 Tiantan Company Information
13.3.2 Tiantan Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.3.3 Tiantan Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Tiantan Main Business Overview
13.3.5 Tiantan Latest Developments
13.4 Pulike
13.4.1 Pulike Company Information
13.4.2 Pulike Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.4.3 Pulike Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pulike Main Business Overview
13.4.5 Pulike Latest Developments
13.5 Greffex
13.5.1 Greffex Company Information
13.5.2 Greffex Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.5.3 Greffex Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Greffex Main Business Overview
13.5.5 Greffex Latest Developments
13.6 CureVac
13.6.1 CureVac Company Information
13.6.2 CureVac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.6.3 CureVac Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 CureVac Main Business Overview
13.6.5 CureVac Latest Developments
13.7 Yebio
13.7.1 Yebio Company Information
13.7.2 Yebio Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.7.3 Yebio Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Yebio Main Business Overview
13.7.5 Yebio Latest Developments
13.8 Sanofi Pasteur SA
13.8.1 Sanofi Pasteur SA Company Information
13.8.2 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Sanofi Pasteur SA Main Business Overview
13.8.5 Sanofi Pasteur SA Latest Developments
13.9 Virbac
13.9.1 Virbac Company Information
13.9.2 Virbac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.9.3 Virbac Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Virbac Main Business Overview
13.9.5 Virbac Latest Developments
13.10 Pfizer Inc.
13.10.1 Pfizer Inc. Company Information
13.10.2 Pfizer Inc. Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Pfizer Inc. Main Business Overview
13.10.5 Pfizer Inc. Latest Developments
13.11 Walvax Biotechnology
13.11.1 Walvax Biotechnology Company Information
13.11.2 Walvax Biotechnology Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Walvax Biotechnology Main Business Overview
13.11.5 Walvax Biotechnology Latest Developments
13.12 Kontec
13.12.1 Kontec Company Information
13.12.2 Kontec Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.12.3 Kontec Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Kontec Main Business Overview
13.12.5 Kontec Latest Developments
13.13 Novavax
13.13.1 Novavax Company Information
13.13.2 Novavax Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.13.3 Novavax Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Novavax Main Business Overview
13.13.5 Novavax Latest Developments
13.14 Sanofi Pasteur
13.14.1 Sanofi Pasteur Company Information
13.14.2 Sanofi Pasteur Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.14.3 Sanofi Pasteur Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Sanofi Pasteur Main Business Overview
13.14.5 Sanofi Pasteur Latest Developments
13.15 Bharat Biotech
13.15.1 Bharat Biotech Company Information
13.15.2 Bharat Biotech Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.15.3 Bharat Biotech Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Bharat Biotech Main Business Overview
13.15.5 Bharat Biotech Latest Developments
13.16 GlaxoSmithKline
13.16.1 GlaxoSmithKline Company Information
13.16.2 GlaxoSmithKline Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.16.3 GlaxoSmithKline Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 GlaxoSmithKline Main Business Overview
13.16.5 GlaxoSmithKline Latest Developments
13.17 Pfizer
13.17.1 Pfizer Company Information
13.17.2 Pfizer Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.17.3 Pfizer Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Pfizer Main Business Overview
13.17.5 Pfizer Latest Developments
13.18 Moderna
13.18.1 Moderna Company Information
13.18.2 Moderna Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.18.3 Moderna Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Moderna Main Business Overview
13.18.5 Moderna Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
